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Despite the recent advances in cancer patient management and in the development of
targeted therapies, systemic chemotherapy is currently used as a first-line treatment for
many cancer types. After an initial partial response, patients become refractory to
standard therapy fostering rapid tumor progression. Compelling evidence highlights
that the resistance to chemotherapeutic regimens is a peculiarity of a subpopulation of
cancer cells within tumor mass, known as cancer stem cells (CSCs). This cellular
compartment is endowed with tumor-initiating and metastasis formation capabilities.
CSC chemoresistance is sustained by a plethora of grow factors and cytokines released
by neighboring tumor microenvironment (TME), which is mainly composed by adipocytes,
cancer-associated fibroblasts (CAFs), immune and endothelial cells. TME strengthens
CSC refractoriness to standard and targeted therapies by enhancing survival signaling
pathways, DNA repair machinery, expression of drug efflux transporters and anti-
apoptotic proteins. In the last years many efforts have been made to understand CSC-
TME crosstalk and develop therapeutic strategy halting this interplay. Here, we report the
combinatorial approaches, which perturb the interaction network between CSCs and the
different component of TME.
Keywords: cancer stem cells, tumor microenvironment, anticancer drugs, chemoresistance, targeted therapyINTRODUCTION
Despite huge progress has been made in the development and optimization of anti-tumor therapies,
cancer remains the second leading cause of death worldwide. Intra- and inter-tumor heterogeneity
represents the main hurdle for cancer treatment. For this reason, the comprehension of the
molecular and phenotypic differences among different cancer types may help to improve theJuly 2021 | Volume 11 | Article 7026421
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been proposed to explain the origin of tumor heterogeneity (1).
According to the stochastic model, each cell within the tumor
mass can become tumorigenic by acquiring specific (epi)genetic
alterations. Conversely, in the hierarchical model tumor
heterogeneity arises from a subpopulation of cancer cells,
termed cancer stem cells (CSCs), able to self-renew and
differentiate into phenotypically and functionally distinct cells.
CSCs share most of the features with normal stem cells, but their
self-renewal capacity is typically deregulated (2, 3). Therefore,
CSCs represent the roots which feed tumor initiation and sustain
metastatic spread, therapeutic resistance and recurrence (4, 5).
Chemotherapy is a pivotal treatment for solid tumors and aims
to counteract all the active proliferative cells, including both
healthy and malignant cells (6). Compelling evidence have
demonstrated that CSCs are endowed with i) high expression
of ATP-binding cassette (ABC) transporter and anti-apoptotic
molecules, ii) aberrant activation of proliferative and survival
signaling pathway and iii) a proficient DNA repair machinery are
the main mechanisms inducing multidrug resistance (MDR) (1).
Interestingly, recent studies have shown that tumor
microenvironment (TME) could generate a protective niche for
tumor cells from drugs, leading to chemoresistance. In addition
to the intrinsic characteristics of CSCs, the interaction with the
TME must be taken into account because it is involved in the
regulation of signaling pathway and resistance to therapy,
representing a potential target for novel therapeutic approaches
(7). In this review, we will illustrate TME protective effects
against chemotherapic drugs and the most updated strategies
for targeted therapies alone or in combination to disrupt the
CSCs/TME interaction.CANCER STEM CELLS AS A SHIELD TO
ELUDE CHEMOTHERAPEUTIC AGENTS
Different hypotheses have been made about the origin of CSCs,
as a direct consequence of (epi)genetic alterations in the healthy
stem cell compartment, or from progenitor/differentiated cells
through the dysregulation of stemness-related pathways (8).
The pioneering studies conducted by Tilland McCulloch in
early ‘60s demonstrated the existence of hematopoietic stem
cells, opening the era of stem cell research (9). Later in 1994,
Lapidot et al., provided the first evidence of CSC presence in
acute myeloid leukemia (AML). AML cells were fractioned
according to the expression of cell surface markers CD38 and
CD34 and the obtained different subpopulations were injected
into immunocompromised mice. They noticed that only the
CD34+/CD38- subpopulation was able to engraft in mice
reflecting many features of human AML (10, 11). The first
demonstration of CSC existence in solid tumors was provided
in breast cancer (BC) (12) and later in brain, colon, thyroid and
other tumors (13, 14), pointing out that cancer cell
transplantation into immunocompromised mice is the gold
standard assay to identify and characterize CSCs (15).
Compelling evidence point out that CSCs are responsible forFrontiers in Oncology | www.frontiersin.org 2the failure of the conventional therapies, due to aberrant
activation of signaling pathways, high expression of efflux
transporters/anti-apoptotic molecules, and enhanced DNA-
damage repair machinery (4, 16, 17).
Stemness-Related Pathways Involved in
CSC Chemoresistance
Deregulation of developmental and proliferative pathways, such
as Hedgehog (HH), Wnt/b-catenin and Hippo, sustains CSC
growth and chemoresistance (18). The HH pathway has been
shown to regulate the properties of CSCs in various neoplasms
through the up-regulation of stemness-related genes (Nanog,
Oct4, Sox2 and Bmi1) (19, 20). In colorectal cancer (CRC) HH-
GLI pathway activation fostered CSC survival and sustained in
vivo growth and metastatic ability (21). In BC, the CD44+/CD24-
subpopulation isolated from tumor xenografts displayed high
expression levels of HH signaling molecules compared to more
differentiated cell subsets (22). In glioma, the activation of Notch
and HH pathway mediated the resistance to temozolomide
treatment in CD133+ CSCs (23). Aberrant activation of the
Wnt/b-catenin signaling pathway has been mainly linked to
development of CRC (24, 25) and detected also in other tumor
types, as hepatocellular and BC (26). Recently, it has been
demonstrated that knockdown of Wnt1 decreases the
expression of CD44, Aldehyde dehydrogenase 1 (ALDH1) and
Sca-1 stemness genes, thus leading to the reduction of CSC
subpopulation and tumor sphere formation in BC cells (27).
Several studies linked Wnt/b-catenin signaling and
chemoresistance (28). The overexpression of Frizzled1 (FZD1),
a receptor of Wnt ligands, increased ABCB1 transporter and
mediates MDR in neuroblastoma and BC (29, 30). Moreover,
LGR5, a Wnt target gene, promoted resistance to 5-fluoruracil
(5-FU) treatment in CSCs (31, 32). Recent studies have revealed
a complex crosstalk between Wnt and Hippo-YAP/TAZ
pathways. Hippo pathway via YAP/TAZ activation led to the
induction of CSC properties in BC cells (33). In a very elegant
study, Cheung et al demonstrated that the Hippo kinases LATS1/
2 and MST1/2 maintain Lgr5+ CSCs phenotype and sustain the
activation of Wnt/b-catenin signaling pathway in CRC (34).
Alterations of Apoptotic Pathways and
DNA Damage Repair Machinery in
Chemoresistant CSCs
Alterations of apoptotic pathways and DNA damage repair
machinery are among the principal mechanisms underlying
CSC-mediated chemoresistance. Apoptosis regulates tissue
development and homeostasis and is finely regulated by a
network of signals that are crucial for cell fate. The ratio
between apoptotic and anti-apoptotic protein levels defines the
sensitivity of malignant cells to apoptotic stimuli and contributes
to CSCs resistance to anticancer treatments (35). A weakened
expression of death receptors (DRs) was observed in CSCs from
different tumors compared to differentiated counterparts. In
AML, the CD34+ CD38- stem-like subpopulation display a
lower expression of FAS and FAS ligand (FAS-L) than CD38+
differentiated cells, triggering chemoresistance (36, 37). FAS andJuly 2021 | Volume 11 | Article 702642
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(GSCs) and the use of a synthetic FAS-L, Apo010, in
combination with temozolomide induced apoptosis in
glioblastoma (GBM) stem-like cells (38, 39). Moreover, the use
of recombinant soluble TRAIL (TNF related apoptosis inducing
ligand), in combination with bortezomib reduced the colony
formation capacity of GSCs and impaired tumor growth in a
mouse model of GBM (40). Unfortunately, the short half-life of
soluble TRAIL in plasma reduces its efficacy. An interesting
approach to overcome this effect is the use of TRAIL-engineered
mesenchymal stromal cells, which induce apoptosis and curtail
the colony forming ability of lung and breast cancer stem-like
cells (41, 42). However, CSCs usually exhibited TRAIL
resistance, due to c-FLIP over-expression. In BC and GBM, c-
FLIP up-regulation sustained resistance to TRAIL therapy and
the use of siRNA specific for c-Flip lessened self-renewal and
tumorigenic potential of breast CSCs (43–45). The inhibitor of
apoptosis (IAP) proteins were found to be over-expressed in
CD133+ GBM stem cells compared to the CD133- compartment
and their inhibition, by using small molecules, enhanced
apoptosis in g-irradiated cells (46, 47). In GBM patients, the
IAP protein, survivin, was demonstrated to be mainly expressed
in patient-derived GBM stem cells compared to differentiated
cells, with a predominant localization in the core of tumor mass
and associated with the expression of CD133, SOX2 and MELK
(48). In addition, our group demonstrated that highly
chemoresistant colorectal CSCs are characterized by the
autocrine production of IL-4 that boosts survivin expression
(49, 50). On the other hand, the dysregulation of Bcl2 family,
composed by anti-apoptotic (Bcl2, Bcl-xL and Mcl-1) and pro-
apoptotic (Bak, Bax, Bid, Bim, Bic, Noxa and PUMA) factors, has
been found in CSCs (51). In particular, the stem-like
compartment expressed higher expression level of Bcl2 and
Bcl-xL compared to differentiated cancer cells (46, 52).
Moreover, in breast CSCs the activation of avb3/Src/Slug
signaling pathway leads to inactivation of PUMA through
SLUG, a PUMA repressor. The pharmacological inhibition of
Src with dasatinib enhanced PUMA expression levels, reducing
self-renewal and colony formation capacity and increasing
sensitivity to apoptosis (53, 54). On the contrary, the
interaction of PUMA with Bcl2 and Bcl-xL limited its anti-
apoptotic activity and a combined treatment of Src and Bcl2
inhibitors increased apoptosis, thus reducing chemoresistance (55).
Chemotherapeutic drugs mainly target differentiated tumor
cells, while sparing CSCs, characterized by a highly efficient DNA
damage response (DDR) system able to repair DNA damage
induced by radio- and chemotherapies (56, 57). In accordance,
cisplatin (CIS) treatment led to an enrichment of CSC
subpopulation in ovarian and lung cancers, confirming that
chemotherapy efficiently eliminates rapidly dividing
differentiated/progenitor cells (58, 59). DNA damage promoted
the activation of ataxia-telangiectasia-mutated (ATM), Rad17,
Chk1 and Chk2 checkpoint proteins. Experimental evidence
showed that CD133+ GSCs are radio-resistant compared to
CD133- tumor cells, due to a more efficient checkpoint protein
activation in response of DNA damage (60). Another studyFrontiers in Oncology | www.frontiersin.org 3reported that GBM stem cells after irradiation increase the
expression levels of L1CAM (CD171), which in turn up-
regulates NBS1, an important component of MRN complex
implicating in the early activation of ATM in response to DNA
damage (61). Knockdown of L1CAM reduced the activating
phosphorylation of ATM and Chk2 in response to IR-induced
DNA damage, sensitizing GBM stem cells to radiation and
reducing in vitro tumor sphere formation (62). In addition to
GSCs, alteration of DDR pathway has been described in CSCs
from different tumor types, including CRC (63). CD133+ lung
cancer cells are resistant to ionizing radiation treatment due to
an up-regulation of genes involved in double strand break repair,
such as Rad51, BRCA1 and Exo1 (64). Moreover, invasive
CD133+ stem-like cells isolated from pancreatic cancer cell
lines displayed higher expression levels of gene involved in the
BRCA1-mediated DNA repair pathway and resistance to
gemcitabine (GEM) treatment compared to CD133-
subpopulation (65). In a syngeneic p53null mice mammary
g land tumor mode l , the L in - /CD29Hi g h /CD24Hi g h
subpopulation was characterized by increased expression levels
of DDR and DNA repair genes (66). Furthermore, Liu et al.
demonstrated that CSCs, isolated from BRCA1-mutant BC cell
lines, displayed resistance to PARP inhibitors and were
characterized by the overexpression of RAD51. The use of a
shRNA targeting RAD51 sensitized triple negative BC cells to
olaparib treatment (67).
Another mechanism of CSC resistance to anticancer therapies
is represented by the up-regulation of detoxifying enzymes and
drug efflux pump expression levels. ALDH superfamily is
responsible for oxidizing aldehydes to carboxylic acids and
retinol to retinoic acid allowing the detoxification from drug
and the reactive oxygen species (ROS). ALDH1 is the main
isoform of the ALDH superfamily enzymes and is one of the
markers used for the identification of the CSCs (68–71). In BC
patients, ALDH1-positive CSCs were selected after neoadjuvant
treatment and their presence within the tumor could predict
resistance to chemotherapy (72). In breast CSCs, the resistance to
doxorubicin and paclitaxel treatment is related to the over-
expression of ABCB1 efflux pump (73). Moreover, ABCB1
confers resistance to carfilzomib in multiple myeloma stem
cells (74). Indeed, high expression levels of ABCB5 were found
in malignant melanoma initiating cell resistant to doxorubicin
treatment (75) (Table 1).
THE CANCER STEM CELLS-TUMOR
MICROENVIRONMENT INTERACTION: A
HIDDEN HURDLE IN CHEMOTHERAPY
EFFICACY
CSCs require the cooperation of surrounding microenvironmental
cells to promote tumor initiation, metastasis formation and drug
resistance. Recent evidence highlighted the importance of TME cell
education and recruitment as essential events for tumor
dissemination. In fact, cancer cells prime stromal cells, which in
turn maintain and boost CSC subpopulation (76). In particular,July 2021 | Volume 11 | Article 702642
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between tumor cells and TME, mainly composed by extracellular
matrix, cancer-associated fibroblasts (CAFs), cancer-associated
adipocytes (CAAs), immune and endothelial cells. In addition to
the intrinsic characteristic of CSCs, the understanding of tumor-
TME cell interactions could provide actionable candidates for the
development of novel therapeutic approaches (Figure 1).
CAF Role in Inducing CSC-Mediated
Resistance to Therapy
CAFs are the major component of TME involved in the complex
network of tumor-stroma evolution and tumorigenesis (77, 78).
Several studies demonstrated that CAFs can originate from the
activation of resident fibroblast or derive from the conversion ofFrontiers in Oncology | www.frontiersin.org 4adipocytes, endothelial cells, pericytes and bone marrow-derived
mesenchymal stem cells (79). CAFs provide numerous molecules,
soluble factors and proteases playing an important role in ECM
synthesis or remodeling, but also pro-inflammatory cytokines,
chemokines, and growth factors. Notably, CAF secreted factors
are involved in a tight crosstalk with CSCs, governing their
self-renewal capacity, plasticity and chemoresistance (80–85).
Several in vitro experiments highlighted that CAFs guarantee a
CSC reservoir in different tumors, such as breast, lung, colorectal,
gastric and liver, enhancing stemmarkers expression (CD44, Sox2,
Bmi-1), sphere formation, self-renewal and sustaining CSC pool
expansion (86–90). Moreover, CAF conditioned medium
influenced the tumorigenic behavior and the aggressiveness of
CSCs (91). For these reasons, CAFs represent a cellular subtypeTABLE 1 | Cancer stem cell biomarkers correlated to chemoresistance.
CSC markers Stemness-related pathways Tumors References
CD133 Hedgehog (HH) CRC 21
CD44+CD24-/low Lin- BC 22
CD133 Glioma 23
CD133 Notch Glioma 23






ALDH activity, SP 30
Neuroblastoma 29
CD44+CD24-/low YAP/TAZ BC 33
Lgr5 CRC 34
Apoptotic molecules








CD133 IAP GBM 22
47
CD133, SOX2 Survivin GMB 48
CRC 49
CD133 Bcl2 family GBM 22
Haematopoietic disorders 54
CD44+CD24-/low BC 53, 55
DNA damage repair machinery
CD133 Chk1/2 Glioma/GBM 60
SOX2 62
CD44v6 TOP-GFPhig CRC 63
ATM GBM 61
SOX2 62
CD133 Rad51 Lung 64
ALDH activity BC 67
CD133 BRCA1 Lung 64
CD133 Pancreatic 65
Detoxifying enzymes /Drug efflux molecules
CD44+CD24-/low ALDH1 BC 72
CD44+CD24-/low and CD133 ABCB1 BC 73
ALDH activity Myeloma 74
CD133 ABCB5 Melanoma 75July 2021 | Volume 11 | Article 702642
Gaggianesi et al. Cutting-Edge Strategies Targeting Cancer/TME Cross-TalkFIGURE 1 | Crosstalk between cancer stem cells (CSCs) and tumor microenvironment (TME) components. Within the tumor mass, a subpopulation of cancer cells,
called cancer stem cells (CSCs), are endowed with high resistance to anticancer therapies, due to elevated expression levels of ABC transporters, anti-apoptotic
proteins and a proficient DNA damage repair (DDR) machinery. Tumor microenvironment (TME), mainly composed by cancer associated fibroblasts (CAFs),
adipocytes, immune and endothelial cells, has a key role in the maintenance of CSC peculiarities. Cytokines and chemokines produced by both CSCs and TME cells
boost cancer cell growth, prompt chemoresistance and promote tumor progression and relapse.Frontiers in Oncology | www.frontiersin.org July 2021 | Volume 11 | Article 7026425
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outcome and to design new target therapies.
CAF-secreted factors, which include chemokines, cytokines,
growth factors, proteins and exosomes, influence and sustain
CSCs aggressiveness by modulating their stemness features.
CCL2 supported CSC self-renewal activating NOTCH signaling
pathway and the co-injection of CAF and breast CSCs into the
mammary fat pads of NOD/SCID/IL-2Rg-null mice enhanced
CSC tumorigenic potential, unveiling the CCL2 driving role in BC
(83). In addition, SDF-1 interacting with its receptor (CXCR4),
highly expressed on CSC surface, regulated stem phenotype
through the activation of Wnt/b-catenin and PI3K/AKT
signaling pathways and boosted the proliferation of CD44+/
CD24- BC cells (92). In agreement, CXCR4+ cells were more
prone to reach the stem phenotype and properties, in comparison
to CXCR4- cells (90).
Among the variety of cytokines and growth factors secreted
by CAFs, a great number of studies highlighted the IL-6 and IL-8
essential role in the maintenance of stem-like features of cancer
cells and in the promotion of tumor growth, metastasis
formation, and chemoresistance (93, 94).
CAFs also supported the aggressive behavior of cancer cells
through the secretion of TGF-b. In different tumor types, TGF-b
induced the acquisition of a stem-like phenotype, promoted
EMT and chemoresistance via the activation of TGF-b/Smad
signaling pathway (88, 95).
Hepatocyte growth factor (HGF), another important
molecules secreted by CAFs, promotes cancer cell invasiveness.
In hepatocellular carcinoma, HGF sustained cancer cell stemness
through the activation of MET/FRA1/HEY1 cascade (89). Our
group recently demonstrated that HGF, SDF-1, and OPN
released by CAFs were able to reprogram CD44v6- progenitor
cells in metastatic CD44v6+ CSCs by activating Wnt/b-catenin
and PI3K/AKT signaling pathways (90).Frontiers in Oncology | www.frontiersin.org 6Synthesis and remodeling of extracellular matrix (ECM)
represents an important function of CAFs in TME. Malanchi
et al. demonstrated in a murine BC model that lung fibroblasts,
activated by infiltrating CSCs, produce periostin which boosts
Wnt pathway sustaining metastatic colonization (96). Moreover,
in a syngeneic BC mouse model S100A4+ lung CAFs secreted
VEGF-A and tenascin-C, which mediate angiogenesis and CSC
survival, respectively (97). In addition to the production of ECM
components, CAFs secreted metalloproteases, a family of
enzymes able to degrade and remodel ECM, favoring cancer
cell invasion (98).
Numerous studies highlighted that CAFs can support CSC
chemoresistance in different solid tumors. Co-culture
experiments performed with freshly isolated colorectal CSCs
showed that CAFs secrete high levels of TGF-b2 and IL-6,
which in turn prompt the transcription of GLI-2, promoting
resistance to 5-fluorouracil/oxaliplatin (5-FU/oxa) treatment
(99). In breast and lung tumors, the CD10+/GPR77+ CAF
subpopulation secreted both IL-6 and IL-8, which induce CSC
enrichment and chemoresistance to CIS treatment (100).
Moreover, in triple negative BC mice models, cancer cells
reprogrammed CAFs through the secretion of HH ligand.
CAFs, in turn, triggered the acquisition of chemoresistance
through FGF5 secretion and the production of fibrillar collagen
(101). In head and neck small cellular cancer, CAF-secreted
periostin bound PTK7, a receptor expressed on cancer cell
surface, favoring CSC invasion and proliferation through the
activation PTK7–Wnt/b-Catenin signaling pathway. Notably,
PTK7/periostin interaction enhanced erlotinib chemoresistance
and the formation of lung metastasis (102). Recently, our group
demonstrated that in colorectal CSCs CAF-secreted cytokines
confer resistance to PI3K/AKT inhibitors (103) (Table 2). Given
the key role of CAFs in both CSC maintenance and drug
refractoriness, the use of therapeutic strategies blocking CAFs-TABLE 2 | Molecular mechanisms prompting cancer stem cell resistance to standard and targeted therapies.
Mechanism of resistance Tumor Molecule secreted Drug References
Cancer associated fibroblasts (CAFs) GLI-2 enhanced expression CRC TGFb2 , IL-6 5-FU/oxa 99
NF-kB pathway BC/lung IL-6, IL-8 CIS 100
Wnt/b-catenin pathway head/neck periostin erlotinib 102
PI3K/AKT and MAPK pathway CRC HGF, SDF-1, OPN PI3K/AKT inhibitors 90, 103
STAT3/NF-kB pathway BC IL-6 trastuzumab 104
Cancer associated adipocytes (CAAs) High MVP expression levels BC CM from adipocytes doxorubicin/ 5-FU/ paclitaxel 105
MAPK pathway BC IL-4 arimidex/ docetaxel+BKM120 106
AKT/MAPK pathways BC Leptin 5-FU 107
MAPK and AKT pathways CRC Leptin 5-FU 108
AMPK/mTOR/JNK pathways BC Resistin doxorubicin 109
Up-regulation of ABCG2 BC CXCL1 doxorubicin 110
Endothelial cells (ECs) Notch pathway Lymphoma Jagged-1 doxorubicin 111
Notch pathway CRC Jagged-1 5-FU/oxa 112
High c-Met expression levels GBM bevacizumab 113
HIF/VEGF pathways CRC VEGF bevacizumab 114
Increase of intratumoral hypoxia LLC sunitinib 115
VEGF-independent angiogenesis Pancreatic cancer FGFs DC101 (anti-VEGFR2) 116
VEGF-independent angiogenesis RCC IL-8 sunitinib 92
NF-kB pathway RCC IL-6 sunitinib 117
AXL and Met signaling RCC sunitinib 118July 2021 | Volume 11 | Article 702642
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cells, trastuzumab treatment activated an IL-6/STAT-3/NF-kB
inflammatory loop, which correlates with the expansion of the
CSC subpopulation. The administration of an anti-IL-6 receptor
antibody reverted the stem-like phenotype of tumor cells (104).
Zong et al. reported that the use of MEDI5117, an anti IL-6
antibody, in combination with chemotherapy or gefitinib impairs
tumor growth in mice injected with NSCLC cells. MEDI5117 also
displayed robust activity against trastuzumab-resistant HER2
tumor cells by targeting the CD44+/CD24- population (119).
A novel strategy to counteract IL-6 downstream pathway is
represented by the use of specific oligonucleotide decoy specific
for STAT3, which display encouraging anticancer effects. In
EGFR inhibitors-resistant NSCLC cells, the treatment with a
cyclic STAT3 decoy (CS3D) impaired in vitro proliferation and
tumor formation (120). Likewise, AZD9150, a STAT3 antisense
oligonucleotide, sustained antitumor activity in lymphoma and
NSCLC preclinical models. Based on these promising results,
AZD9150 was used as single agent in a Phase I clinical trial
including patients with advanced lymphoma and NSCLC (121).
Moreover, the double inhibition of IL-6 and IL-8 in combination
with docetaxel in CD10+/GPR77+ CAFs impaired tumor growth
in a patient-derived xenograft (PDX) model of BC (100). In
human BC PDX, the use of a specific antibody against IL-8
receptor, CXCR-1, or an inhibitory molecule against to CXCR-1
and CXCR-2, repertaxin, favored the eradication of CSC pool,
thus impeding tumor progression. In particular, ALDH+ and
CD24-/CD44+ levels were reduced by ≥ 20% in 4/17 and 9/17
patients (122). Two independent research groups described that
the use of CXCR-2 inhibitors, AZ13381758 and SB225002,
suppresses tumor progression and hampers chemotherapy
resistance in BC and pancreatic adenocarcinoma, respectively
(123, 124).
The use of smoothened inhibitors (SMOi), in combination
with docetaxel, in triple negative BC PDX and in a Phase I
clinical trial (EDALINE) reduced metastasis formation and
displayed clinical benefits, respectively (101). In addition,
vismodegib, a HH inhibitor, triggered apoptosis and decreased
both CAF and CSC proliferation in breast, colon and prostate
cancer (125–127). In head and neck cancer, the combination of
anti-PTK7 and erlotinib highly reduced tumor growth compared
to single agent treatment (102).
In gastric cancer, TGFb1 neutralizing antibody or TGFbR
inhibitor (Ki26894) reduced the side population fraction, able to
exclude fluorescence dye, even in presence of CAF conditioned
medium (88). Alike, treatment with AMD3100 (plerixafor), a
CXCR4 antagonist, blocked SDF1/CXCR4 interaction leading to
a regression of CSC subpopulation in breast, colon and prostate
cancer (125–127). A Phase I study on a cohort of cancer patients
with worse prognosis showed that treatment with a cMET pan-
inhibitor, capmatinib (INC280), displays anticancer activity in 8/
44 patients (128). In preclinical studies, treatment with WNT/b-
catenin inhibitors, iLGK974, Wnt-C59, and cyclosporin A,
impaired CSC survival in different cancer types (129–131). In
this context, we have recently demonstrated that the use of a
variant of BMP7 with enhanced stability (BMP7v) induced theFrontiers in Oncology | www.frontiersin.org 7differentiation of CD44v6+ cells, suppressed Wnt pathway
activity and sensitized CSCs to standard and target therapies
(132). Recently, we demonstrated that cytokines secreted by
CAFs boosted resistance to PI3K/AKT inhibitors in colorectal
CSCs and this protective effect was overcome by the triple
targeting of Her2, PI3K and MEK (103).
Interestingly, new therapeutic approaches focus on the direct
depletion of CAFs. The targeting of FAP+ CAFs could represents
a new promising target therapy (133). In agreement, FAP+
CAF inhibition and depletion with the use of the dipeptidyl
peptidase inhibitor PT100 led to a reduction of the crosstalk
between CAF and pro-tumorigenic immune or endothelial
cells by enhancing oxa treatment efficacy in colon cancer mice
models (134). Interestingly, FAP could be used as an antigen for
CAR-T anticancer treatment strategy. For instance, treatment
with CAR-T against FAP+ CAFs promoted growth arrest in in





Adipose tissue (AT) is a specialized soft connective tissue
consisting of about 90% of adipocytes cells and for the
remaining part by adipose derived stem cells (ADSCs),
endothelial cells, pericytes, fibroblasts and immune cells
(macrophages, dendritic cells, lymphocytes). AT can be divided
according to anatomic localization in three different subtypes:
subcutaneous, visceral and intramuscular. In addition, adipose
depots may be sub-classified in white (WAT) and brown AT
(BAT), which is characterized by a dark color due to the presence
of vessels and a high number of mitochondria (136). For these
reasons, BAT is mainly implicated in thermogenic regulation,
maintaining the appropriate balance between energy storage and
consumption. AT originates from the mesoderm, whose cells
give rise to adipocyte and the myogenic lineages. Specifically,
white adipocytes derived from the adipogenic MYF5 negative
cells, whereas brown adipocytes from myogenic MYF5 positive
cells (137). White and brown cells could be discriminated in
accordance with the expression of specific markers, with white
adipose cells expressing leptin and S100B, lacking UCP-1
expression, and brown adipose cells characterized by PPAR
gamma and UCP-1 (138). In the last years, WAT, which was
traditionally considered as an energy storage tissue, due to the
triglycerides and cholesterol contained in intracellular droplets,
has been demonstrated to represent the biggest human endocrine
organ, with the production and release of hormones, growth
factors, cytokines and adipokines. Accordingly, a conspicuous
secretion of these factors is observed in obesity conditions (139,
140). Nowadays, obesity represents a global health problem and
constantly increases in all countries of the world (141, 142). It has
been demonstrated that overweight and obesity correlate with
the onset of several solid tumors, including esophagus,
pancreatic, colon, breast, endometrium, ovarian and kidney,
suggesting an association between these conditions and tumor
initiation (143, 144). In obese subjects, adipocytes increase theirJuly 2021 | Volume 11 | Article 702642
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ATs, whereas only visceral is characterized by an increase of
adipocyte number (hyperplasia) (145).
In obese conditions, WAT secrete high amount of hormones,
adipokines and pro-inflammatory cytokines, such as leptin, IGF-1,
HGF, TNF-a, IL1b, IL-4, IL-6, IL-8, plasminogen activator inhibitor
1 (PAI-1) and CCL-2. This promotes both a chronic inflammatory
state and a tumor-permissive microenvironment, which in turn
induce tumorigenesis, neo-angiogenesis via VEGF release and
metastatic progression (106, 134, 146–150). Furthermore,
adipokines locally recruit monocytes, macrophages, lymphocytes
and other immune cells, which increase the inflammatory status in
the AT particularly in obese subjects (151). The adipocytes’ role in
TME has been broadly studied in the context of BC. The established
crosstalk between BC cells and the close AT cells increases the
production of cytokines with proinflammatory activity. Picon-Ruiz
et al. demonstrated that tumor cells, after exposure to
proinflammatory cytokines, are characterized by the activation of
ALDH1 and an increment of mammosphere formation capacity,
which are correlated with the increase of CSC number and
metastasis formation in in vivo settings. These processes are
driven by Src oncogene, which activates the transcription of
SOX2, MYC and NANOG, well-known stem cell markers (152).
In agreement with these observations, we have previously
demonstrated that the release of IL-4 sustains breast CSCs
invasion, tumorigenic potential, and drug resistance (106).
Moreover, in obese conditions, adipocytes released elevated levels
of leptin, which trigger the activation of many stemness-related
molecular pathways, as Notch,Wnt/B-catenin, OCT4,SOX2, Nanog
and ALDH1 up-regulation (153–156). In intestinal epithelial cells,
the activation of Wnt pathway determines the expansion of crypt
stem cells and favors progenitor proliferation (153–156). Breast
CSCs harness higher lipid metabolism than differentiated cancer
cells and used long chain fatty acids as an energy source (157). This
population is characterized by an increased b-oxidation activity,
which produces numerous metabolic intermediates used in ATP
production (154). Recent studies have shown that ovarian and
colorectal CSCs retain a high amount of fatty acids within lipid
droplets to maintain their stem-like features (158). This population
is rich of monounsaturated fatty acids (MUFAs), generated by
stearoyl-CoA desaturase-1 (SCD1), which are metabolic markers of
CSCs (159, 160). The inhibition of SCD1 decreased ovarian CSC
phenotype, impairing the expression of SOX2, Nanog and Oct4,
sphere forming capacity and tumorigenic potential (161–163). In
melanoma, lipids released by adipocytes induced metabolic
reprogramming, enhancing cell proliferation (164).
In addition, tumor cells prime peritumoral adipocytes,
boosting intense lipolysis. In fact, these adipocytes, called
cancer associated adipocytes (CAAs), show both in vitro and
in vivo smaller cell sizes and irregular shapes with an expanded
ECM and over-expression of collagen IV. They are also
characterized by an increased secretion of proinflammatory
factors and numerous high-energy metabolites, free fatty acids,
ketone bodies, pyruvate, and lactate (165, 166). Several studies
show that CAAs activate Wnt/b-catenin pathway, leading to the
loss of terminal adipocyte differentiation markers such asFrontiers in Oncology | www.frontiersin.org 8adiponectin (APN), resistin, hormone-sensitive lipase (HSL)
and adipocyte protein 2 (aP2) (166). In particular, CAAs have
some characteristics of the senescence-associated secretory
phenotype (SASP), such as the release of proinflammatory
factors (167). CAA-released leptin determined the activation of
STAT3-CPT1-fatty acid b-oxidation (FAO) in CSCs, with an
increased use of fatty acids as an energy source. The in vivo
blocking of this signaling pathway led to a reduction of stem-like
features and a re-sensitization of breast tumor cells to
chemotherapy (107).
Recent studies showed that obesity could be associated with
treatment-related toxicity (168), thus, lower doses of
chemotherapeutic drugs are administered to obese patients,
compromising therapy efficacy and leading to resistance
development (169, 170). These observations highlighted that
the body max index (BMI) is not the appropriate parameter to
determine the dose of chemotherapy, because it does not take
into account the altered pharmacokinetics and pharmacodynamics
in obese patients. A meta-analysis revealed that obese patients
treated with full chemotherapy doses, estimated using actual body
weight, showed lesser toxicity compared to normal weight subject
(171). Lehuédé et al. observed that adipocytes promote in vitro
resistance to doxorubicin, paclitaxel and 5-FU in BC cells and this
phenomenon is amplified by adipocytes isolated from obese women
(105). It has been demonstrated that the adipocytes, to accomplish
their protective effect on BC cells treated with doxorubicin, increase
the production and secretion of resistin mediating AMPK/mTOR
and JNK signaling pathway activation (109). In addition,
doxorubicin may influence adipocyte functions, deregulating
adipokine secretion and thus altering lipogenesis and lipolysis
(170). Yeh et al. observed that pre-adipocytes promote
doxorubicin resistance in triple negative BC by secreting CXCL1,
which determines over-expression of ABCG2 (110). Moreover, high
concentrations of leptin increased colorectal CSCs survival and the
resistance to 5-FU treatment (108) (Table 2).
In addition to cytotoxic drugs, adipocytes are implicated in the
resistance to multiple therapies, including radiotherapy, hormonal
therapy, immunotherapy, and chemotherapy (172–174). CAAs
expressed high levels of PD-L1 and in turn protected cancer cell
from the anti-tumor activity ofCD8+T lymphocytes (151).Ofnote,
the use of immune checkpoint inhibitors in BC displays limited
efficacy, probably due to the presence of surrounding AT. The
inhibition of adipogenic processes increased anti PD-L1 or anti
PD-1 activity (175). Moreover, it was demonstrated that IL-6
secreted by mammary adipose tissue up-regulated Chk1 signaling
pathway in BC cells, promoting resistance to radiotherapy
(138). Therefore, the targeting of tumor-released factors which
induce the activation of adipocytes in CAAs could improve
patient outcomes. In BC cachectic patients, the secretion of
miR-155 by tumor cells restored adipocyte metabolism, reducing
PPARg expression levels, and was associated with tumor
progression. The administration of propranolol impaired the
release of exosomes containing miR-155, thus restoring PPARg
in adipocytes (176, 177).
Moreover, targeting the metabolic dependence of cancer cells
on adipocytes could be a therapeutic strategy to lessen tumorJuly 2021 | Volume 11 | Article 702642
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acid transport protein 1 inhibitor impaired the invasive capacity
of tumor cells promoted by adipocyte conditioned medium
(179). In addition, CD36 inhibition in ovarian cancer cells
reduced their in vitro and in vivo invasive capabilities
sustained by CAAs (180). Moreover, Masko et al. pointed out
that the combination of standard treatments with drugs
interfering with adipocyte metabolism, like statins, has
promising therapeutic relevance in prostate cancer treatment
(181, 182). The administration of a high fat diet, instead of a
normal one, in mice treated with diethylnitrosamine promoted
hepatocellular carcinoma development, increasing STAT3
activation and IL-6 production. This phenotype was
counteracted using acyclic retinoids (183, 184). Metformin is
an anti-hyperglycemic agent, indicated for obesity-related type 2
diabetes, which determines the inhibition of the hepatic
gluconeogenesis pathway, through the activation of AMPK.
Moreover, metformin reduced the circulating levels of
androgen, estrogen, insulin and sensitized BC cells to chemo
and radiotherapy through a selective killing of stemness
compartment (NCT02874430) (185–187).
Immune Cells Rewiring Therapies
Immune system is an interesting network composed of
specialized immune cells (ICs), cytokines, chemokines, and
lymphoid organs, which, all together, contribute to immune
response. The principal function of immune system is to
discriminate “self” from “non-self” components. In TME, ICs
affect both cancer development and immunological surveillance,
influencing patients’ clinical outcome (188). ICs are classified in
effector and non-effector cells, with the first category including
natural killer (NK) cells, B and T lymphocytes, involved in the
adoptive immune response along with the killing of cancer cells.
The presence of T cytotoxic CD8+, T helper 1 (Th1) CD4+, B and
NK cells within the TME is associated with a positive patients’
outcome in many cancers (189, 190). It is well known that NK
cells act directly on the tumor cells, hampering their proliferation
and dissemination. Compelling evidence demonstrated that NK
cells eradicate CSCs at mestatatic sites, preventing tumor
progression and relapse (191–194). Differently, the reduction
of NK cells was associated with a worse outcome (195).
Non effector cells include antigen-presenting cells (APCs),
regulatory T cells (Treg), tumor-associated macrophages
(TAMs) and myeloid-derived suppressor cells (MDSCs), which
support tumor growth, progression, and dissemination,
hampering immune response.
The most abundant IC subset within the TME is represented
by TAMs, which modulate the innate immune response in the
context of tumor. TAMs own a phenotypic plasticity, thus transit
from M1 to M2 phenotypes, and viceversa. M1 TAMs are
involved in activated proinflammatory pathway and counteract
tumor growth, while the M2 are engaged in anti-inflammatory
response, largely promoting angiogenesis and tissue remodeling
and sustaining tumor progression (196, 197).
Several studies highlighted that M2 TAMs are characterized
by the expression of specific markers, such as CD163 and CD206Frontiers in Oncology | www.frontiersin.org 9(198). In BC the release of TNF-a, IL-6 and IL-1b in the TME
sustained M2 macrophages, which boost tumor initiation,
dissemination and metastasis formation (199). In addition,
Rodriguez-Garcia et al. highlighted the role of folate receptor b
(FRb) in TAMs cells. They demonstrated that immunosuppressive
M2 TAMs expressing FRb promote tumor progression in a mouse
model of ovarian cancer, pointing out FRb as a potential therapeutic
target in combination with chemo- or immunotherapy (200).
Furthermore, the expression of FRb in M2 TAMs correlated with
a poor prognosis also in pancreatic cancer (201). A recent study
showed that BC cells, through TNF-a and IL-1b releasing in TME,
induce the production of CCL8 by pro-tumorigenic TAMs and this
crosstalk correlates with worse outcomes (202). These data confirm
thatM2 phenotype of TAMs plays a pivotal role in sustaining tumor
growth and therefore could be a potential target. Overall, many
studies highlighted that TAMs are responsible, in addition with
other factors and cells available in the TME, for the increase of CSC
subpopulation, leading to chemotherapy resistance. The induction
of EMT and the over-expression of stem cell markers, such as
CD90/Thy1 and EphA4, mediated the crosstalk between CSCs and
TAMs. In addition, in different types of cancers and in particular in
BC, the maintenance of a stem-like phenotype is also correlated to
the presence of M2 macrophages in the TME (203, 204). In
osteosarcoma, Xue-jing Shao et al. described the contribution of
CD209+ M2 macrophages in tumor initiation and CSC
maintenance, corroborating the possibility that the blockage of
M2 macrophages depletes CSC subpopulation in the tumor bulk
and, at the same time, inhibits tumor progression (205).
In liver cancer, the activation of oncoprotein Yes-associated
protein (YAP) in CSCs correlated with both tumorigenesis and
TAM recruitment, indicating that the blocking of M2
macrophage or YAP could be an efficacious therapeutic
strategy (206).
In BC the inflammatory process predisposes to the malignant
transformation, inducing the release chemokines, such as IL-8
and growth-regulated oncogene (GRO), which activate JAK/
STAT3 pathway and in turn maintain CSC-like cell phenotype
(207). Larionova et al. dissected the contributions of M2
macrophages in chemoresistance, showing that the depletion of
M2 macrophages or M2-to-M1 re-polarization improves therapy
efficacy of conventional cytotoxic drugs and/or immunotherapy,
enhancing immune response (197).
It is widely demonstrated that cytotoxic chemotherapeutic
drugs weaken immune sys tem homeostas i s (208) .
Simultaneously, over the last ten years, several studies
highlighted the effects of chemotherapeutic agents regarding
increased immunogenicity of human cancer cells and the role
of chemotherapies in activating antitumor immune responses
(209, 210). Different studies shed light on the role of NK cells
within tumors and the influence of TME and chemotherapy on
innate lymphoid cells. The high presence of NK cells in the TME
correlate with an increased patients’ survival in different types of
cancer, such as HER2-positive and triple negative BCs (211). It
has been demonstrated that NK function could be regulated by
chemotherapy (212). Recent studies have reported that different
chemotherapeutic compounds, such as GEM, positively regulateJuly 2021 | Volume 11 | Article 702642
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enhanced the release of INF-g and at the same time activated NK
cells (213). In in vivo models of pancreatic cancer, the use of
GEM as adjuvant chemotherapy improved mice overall survival
with a reduction of tumor burden bulk. Thereafter, GEM
induced a decrease of MDSCs and, on the other hand,
increased the anti-tumor capability of NK cells (214, 215). In
the last decades, to eradicate cancer cells many therapeutic
strategies were focused on the re-activation of ICs, in
particular of T cells. Cancer immunotherapies comprehend
different approaches including the immune checkpoint
blockade, with anti programmed death 1 (PD-1)/PD-ligand 1
(PD-L1)/cytotoxic T lymphocyte antigen 4 (CTLA4) antibodies,
and adoptive cellular therapies (216). The following data
illustrate that the use of cytotoxic chemotherapy combined
with immunotherapy could block signaling factors or targets
essential for CSC-mediated tumor progression and dissemination
(190, 217).
In order to counteract fast cancer cell proliferation and
enhance immune response, Orecchioni et al. tested the
synergic effect of 5-FU, cyclophosphamide (CPX) or
vinorelbine in combination with checkpoint inhibitors. In
immunocompetent mice, the treatment with all the three
chemotherapic drugs influenced the number of circulating ICs,
in particular reducing MDSCs, APC cells, Treg, whereas
increasing NK cells. The combination of chemotherapy and
anti PD-L1 in mice injected with triple negative BC and B cell
lymphoma cells reduced tumor growth and metastasis formation
compared to the control group (218).
Many studies have been carried out to characterize the
immunomodulatory properties of GEM. In pancreatic cancer,
GEM induced a decrease in MDSCs and Treg, albeit did not
counteract effector lymphocytes. Although GEM influences
infiltrating ICs, generating an unfavorable condition for tumor
growth, it was not sufficient as single agent and needed to be
combined with immunotherapy to enhance immune response
(219). In fact, in in vivo models GEM in combination with
immunotherapy reduced the number of immunosuppressive
cells, enhancing CD8+ T cells and promoting tumor cell
elimination (220). These results pointed out that GEM is an
immune checkpoint inhibitor-compatible drug, and this
combination treatment reactivates the immune response with
the goal of killing active proliferating cells (221).
Chemotherapy resistance is nowadays a sensitive issue that
led several scientists to look for the causes of this phenomenon
and the possibility to counteract the failure of chemotherapy
drugs l inked wi th the CSC subgroup . In NSCLC
adenocarcinoma, the use of pemetrexed firstly stimulated the
host antitumor immunity and simultaneously induced in vitro
immunogenic cancer cell death (ICD), leading to improved
antitumor immune response (222). In the KEYNOTE–021G
trial, the use of pemetrexed and carboplatin (CARB) plus anti
PD-1 antibody promoted immune response through the
recruitment of infiltrating T cells, the reduction of APC cells,
as well as elicited ICD in patients affected by NSCLC, improving
their clinical outcome (NCT 02039674).Frontiers in Oncology | www.frontiersin.org 10It has been demonstrated that CIS, oxa and CARB are able to
stimulate antitumor immunity by promoting the enhancement
of CD8+ T and APC cells with concomitant down-regulation of
Treg and MDSC subpopulations. This effect, prompted by
platinum derivatives drugs, improved the sensitivity of tumor
cells to immunotherapy (223).
In bladder cancer cell lines, the use of CIS increased the
expression level of PD-L1 through the activation of c-Jun, one of
the activator protein-1 (AP-1) subunits, via ERK1/2. These data
showed that chemotherapy in combination with immunotherapy
(anti PD-L1) preempts cancer relapse blocking AP-1 oncogene
factor (224).
The Keynote-407 multicentric study investigated the use of
immune checkpoint inhibitors alone or in combination with
CARB and paclitaxel in squamous NSCLC patients. The
response rate and median progression-free survival increased
in patients treated with checkpoint inhibitors plus chemotherapy
instead of placebo groups (NCT02775435). The use of these
combinatorial regimes recruited T, NK, and APC cells with a
concomitant reduction of MDSCs and Treg in the TME (225).
The results of a Phase III clinical trial, which includes recurrent
inoperable or metastatic triple-negative BC patients, reported that
pembrolizumab plus chemotherapy (paclitaxel, GEM) improved
the median progression-free survival (NCT02220894) (226).
Moreover, in an ongoing Phase III randomized trial in patients
affected by metastatic CRC the use of chemotherapy (FOLFOX)
in combination with immunotherapy (atezolizumab, anti
PD-L1) was tested in order to hamper cancer progression and
improve immune system response, in particular cytotoxic CD8+
T cells (NCT02912559) (227). All these data highlighted that
immunotherapy, in association with standard chemotherapy, has
erupted as a novel therapeutic strategy to counteract tumor growth
and chemoresistance.
In addition to the use of immune checkpoint inhibitors,
another promising therapeutic approach is the chimeric
antigen receptor T-cell (CAR-T) therapy. This methodology is
based on the use of patients T cells engineered with vectors
carrying a CAR specifically expressed on cancer cells. This
genetic modification allows T cells, after re-infusion in
patients, to efficiently recognize and kill cancer cells (228). To
date, five different generations of CARs, characterized by
differences in their intracellular domain, have been developed.
Specifically, the first generation of CARs presented only the
CD3z domain, which in the second generation was conjugated
with a costimulatory domain, such as CD28 or 4-1BB, to
improve their proliferation and cytotoxic potential. The third
and fourth generation differed from the second generation for
the addition of CD137/CD134 or IL-2 inducer domain,
respectively. To improve CAR-T proliferation and survival, the
last generation display a STAT3 inducer domain in combination
with CD3z-CD28 and IL-2 inducer (229, 230). Promising data
showed that CAR-T cells, engineered for the most abundant
surface antigen expressed on CSCs, efficiently target cancer cells
mainly in liquid tumors. CAR-T cell-based clinical trials displayed
huge remission rates in patients with B cell hematologic
malignancies (231). In the ELIANA trial, children and youngJuly 2021 | Volume 11 | Article 702642
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were infused with autologous T cells engineered with a CD19 CAR
(CTL019, tisagenlecleucel), achieving durable remission with
transient toxic effects (NCT02435849) (232). The anti CD19
CAR-T cell therapy also displayed remarkable results in adult
patients with diffuse large B-cell lymphoma (DLBCL)
(NCT02445248) (233). Despite the encouraging results obtained
in the treatment of hematological tumors, limited successes have
been reached with solid ones. This is probably due to the
immunosuppressive role of TME and the heterogeneous
expression of targetable antigens (234). Nevertheless, several
CAR-T clinical trials have been approved for the treatment of
solid cancers. The high expression levels of EpCAM have been
associatedwith local growth and dissemination in different cancers,
including breast and colorectal tumors (230). Zhang et al. described
that use of CAR-T cells, targeting EpCAM+ cancer cells, induces
tumor strinkage in in vivoCRCmodels (235).Moreover, inaPhase I
clinical trial the use of a CD133 CAR-T cells induced, after the first
infusion, the reductionof tumorgrowthand thepartial remissionor
stable disease for the treatment in hepatocellular, pancreatic and
CRC patients (NCT02541370) (236). Besides hitting cancer cells,
CAR-T could also be engineered to target components of TME. In
murine ovarian carcinoma cell lines, the use of CAR-T targeting
FRb induced a selective depletion of M2 TAMs and, at the same
time, led to the recruitmentof inflammatory cytokine andprecursor
myeloid cells. Despite the clinical benefits obtained in term of
durable remission, the majority of CAR-T cell therapies displayed
high grade toxic effects, such as cytokine-release syndrome and
neurotoxicity (237, 238). Therefore, the next milestone on CAR-T
cell therapies is the optimization of clinical approaches and
engineering strategies to improve safety and efficacy.
Role of Tumor Angiogenesis in
Chemotherapy Failure
The aberrant and rapid growth of cancer cells requires a
continuous demand of nutrient and oxygen, which generate
hypoxic area in the TME. To restore an adequate oxygen
supply, CSCs boosted HIF-1A expression levels which mediate
the secretion of VEGF-A, SDF-1 and HGF, recruiting VEGF
receptors (VEGFRs)-expressing endothelial cells (ECs) and
promoting tumor angiogenesis (239–241). Through this
process, VEGF signaling activates the proliferation and survival
of ECs, determining the increase of vessel permeability and
supporting the metabolic needs of cancer cells (242).
Moreover, the VEGF secreted by CSCs recruited mesenchymal
stem cells inducing their differentiation into ECs (243).
These observations indicate that CSCs play a fundamental
role in determining the TME through an important crosstalk
with mesenchymal cells and ECs associated with the tumor. In
normal conditions, angiogenesis, which has key role during
embryonic development and tissue repair, is finely regulated by
a poise between pro- and anti-angiogenic factors (244). This
process is characterized by a dynamic and complex sequence of
events which involve two main cells type: proliferating stalk cells
and the highly invasive and motile endothelial tip cells. At the
end of vessel formation, pericytes and vascular smooth muscleFrontiers in Oncology | www.frontiersin.org 11cells are recruited to stabilize newly formed blood vessels (245).
The alteration of normal angiogenesis is a hallmark of cancer
which leads to important changes and transformation inside
TME and is connected with tumor progression (246). In 1971,
Folkman used for the first time the expression “tumor
angiogenesis” to describe blood vessel sprouting mediated by
activated ECs nearly tumor mass (247). The new tumoral vessels
are characterized by chaotic organization and weak interactions
between pericytes and ECs favoring vascular leakiness, which is
one of the most important barriers for efficient drug delivery in
solid tumors (245, 248, 249). Several studies described that CSCs
could trans-differentiate and promote the formation of new
vessels without the recruitment of ECs. In the 1999, Maniotis
et al. described for the first time this phenomenon, called
vascular mimicry, in melanoma (250). Thereafter, other groups
described the trans-differentiation of CSCs in ECs and pericytes
in other tumors, like GBM, colon, and BC (4, 243, 251–253).
Calabrese et al. described a close ECs-brain CSCs interaction in
the perivascular niche, which maintains the self-renewal capacity
of CD133+ stem-like cells and supports xenograft tumor growth.
The treatment with anti-angiogenic drugs impaired CSC features
(254). In a 3D system, brain ECs secreted IL-8 which promotes
the expression of stem cell markers and boosts the invasive
potential of patient-derived GBM cells (255). Moreover, ECs
isolated from different organs increased the stem-like phenotype
of CRC cells and the expression levels of OCT4 and NANOGP8
mediated by AKT activation (256). Many studies highlighted the
key role of NOTCH signaling pathway in ECs/CSCs cross-talk,
which prompts stem-like phenotype and tumor progression in
cancer cells (257).
In GBM, the juxtacrine signaling between NOTCH ligand-
expressing ECs and tumor cells exposing Notch1 receptor
boosted in vitro and in vivo growth of cancer stem-like cells
(258). Cao et al. pointed out that FGF4, produced by lymphoma
cells, induces the expression of Jagged-1 on ECs, which in turn
promotes Notch2 activation in cancer cells, increasing their
tumorigenic and invasive capacity (111). A similar mechanism
has been described in breast CSCs (259, 260). In a
complementary manner, ECs released a soluble Jagged-1 which
activates Notch signaling in colorectal CSCs, enhancing their
tumorigenic and metastatic potential (112).
The below reported studies pointed out that ECs not only
promote stem-like phenotype in cancer cells, but also play a key
role in the resistance to chemotherapy. The activation of Notch
pathway triggered by ECs confers resistance to doxorubicin
treatment in aggressive lymphoma cells (111). Moreover, EC
conditioned medium drove refractoriness to 5-FU and oxa
treatment in colorectal CSCs (112). Therefore, the possibility
to counteract chemoresistance mediated by ECs/CSCs
interaction could ameliorate the management of cancer
patients. Compelling evidence showed that anti-angiogenic
treatments not only contrast the formation of new blood
vessels, but also improve the quality of existing blood vessels,
enhancing blood perfusion and consequently the exposure of
cancer cells to chemotherapeutic treatments (261). The majority
of anti-angiogenic therapies is represented by monoclonalJuly 2021 | Volume 11 | Article 702642
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compounds targeted intracellular components, inhibiting their
activation (261).
In the last decades, numerous anti-angiogenic drugs have
been tested in clinical trials and approved by the FDA.
Bevacizumab is a humanized monoclonal antibody directed
against VEGF-A, approved in 2004, and used in clinic for
treatment of different tumors, such as GBM, colorectal, ovarian
and BC (262, 263). Bevacizumab prevents the VEGF-A/VEGFR
interaction and thus impairs the activation of VEGF signaling
pathways in ECs. In vivo studies have shown that bevacizumab
inhibited the spouting of blood vessel, induced the regression of
newly formed vessels, and normalized the morphology of
preexisting ones to improve the administration of cytotoxic
chemotherapy (242). However, the treatment with bevacizumab
did not display significant improvement of patients’ overall
survival in advanced BC (264). The inefficacy of bevacizumab
treatment was also observed in colorectal and brain tumors due to
the increased expression levels or activation of alternative
angiogenic factors and signaling pathways, respectively (113,
114). In particular, Lu et al. demonstrated that in GBM CSCs,
VEGF inhibits cell invasiveness by blocking HGF receptor (Met)/
VEGFR2 interaction and recruiting PTP1B phosphatase, which
promotes Met dephosphorylation. The treatment with
bevacizumab led to Met signaling pathway activation and to the
acquisition of a mesenchymal-like phenotype in GBM CSCs
(265). Although angiogenesis inhibition initially reduce
tumor growth and prevent metastasis formation, these effects
are transitory and associated with tumor relapse and
recurrence (266).
There are several explanations for the failure of anti-
angiogenic therapies. One possible cause is the induction of
intra-tumoral hypoxia related to decreased number of blood
vessels and the over-expression of HIF-1A, which promotes and
sustains CSC features and paradoxically reactivate neo-
angiogenesis (267, 268).
These observations suggest that anti-angiogenic therapy used
as single agent not only favors tumor growth and progression,
but also induces therapy resistance. In fact, angiogenic inhibitors
induced deep changes in vascular morphology involving the
down-regulation of junction proteins and a reduction of pericyte
number and functionality (115).
Another important limiting factor of anti-angiogenic drug
efficacy is the activation of VEGF-independent pro-angiogenic
signaling pathways in pancreatic tumors (116).
Other possible strategies able to interfere with tumor
angiogenesis consist in the use of tyrosine receptor kinase
inhibitors molecules (269). Sorafenib is an inhibitor of
numerous tyrosine kinases, including Ras and VEGFR family
and platelet-derived growth factor receptor b (PDGFR-b). In a
Phase III study, the treatment with sorafenib increased the
overall median survival of hepatocellular carcinoma patients
(270). Moreover, in the DECISION trial patients with
radioactive iodine-refractory thyroid cancer treated with
sorafenib display an improved progression free survival
compared to the placebo group (NCT00984282) (271).Frontiers in Oncology | www.frontiersin.org 12Unfortunately, mechanisms of resistance to sorafenib
treatment similar to those described above for bevacizumab
have been reported (272, 273). In addition, the intratumoral
hypoxia generated by sorafenib treatment enhanced the
expression of PD-L1 in cancer cells and the recruitment of
TAMs (274).
Another tyrosine kinase inhibitor used as anti-angiogenic
molecule is sunitinib, which targets PDGFR, VEGFRs and c-
kit. Suninitib has been approved for the treatment of imatinib-
resistant gastrointestinal stromal tumor (GIST) and metastatic
renal cell carcinoma (RCC), displaying an increased response
rate compared to placebo patient group (275). Nevertheless,
patients rapidly acquire resistance to treatment (276). Huang
et al. generated a sunitinib-resistant RCC xenograft model and
observed high microvessel density together with increased serum
levels of IL-8, suggesting that patients with elevated IL-8 levels
display intrinsic resistance to sunitinib (277). Moreover,
sunitinib treatment induced a stem-like phenotype and
refractoriness in RCC cells through the activation of PAK1/
NF-kB/IL-6 signaling axis (117). In addition, the chronic
administration of sunitinib in RCC cells promoted EMT,
invasion and angiogenesis via the activation of MET and AXL.
This sunitinib-induced phenotype was suppressed by
cabozantinib treatment (118) (Table 2).
Based on the poor clinical efficacy of VEGF pathway inhibitors,
in the last years alternative strategies have been tested to impair
tumor angiogenesis. Small molecules (rebastinib) and monoclonal
antibodies (MEDI3617, demcizumab, enoticumab and
MEDI0639) targeting ANGPT2/TIE2 and Notch ligand–receptor
interactions have been tested and approved for the treatment of
advanced solid tumors (278, 279).
Given that CSCs can activate ECs through different stimuli,
the simultaneous targeting or the subsequent multiple targeting
of several angiogenic factors could represent an important
perspective in the innovation of anti-angiogenic therapies
avoiding the above described resistance mechanisms (261). In
particular, in many clinical trials the treatment with anti-
angiogenic compounds displays clinical effects only in early
stage, due to a ‘selection’ of functional vessels among the newly
tumor vessels. Therefore, this treatment-induced ‘therapeutic
window’ could be an advantage for the administration of
standard and targeted therapies (278).
Another important therapeutic strategy used to counteract
the resistance to the combination of anti-angiogenic and
cytotoxic drugs is the metronomic chemotherapy, based on the
continuous administration of low chemotherapy doses. This
approach hinders CSC/TME interactions, targeting both cancer
cells and tumor-associated ECs (261, 280).CONCLUDING REMARKS AND
FUTURE PERSPECTIVES
Despite the great advances made in early diagnosis and the
development of targeted therapies, which increase patients’July 2021 | Volume 11 | Article 702642
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mainly due to primary or acquired resistance to chemotherapeutic
drugs and the presence of TME. Compelling evidence highlights
that the inefficacy of anti-cancer therapy results from the
refractoriness of a subpopulation of tumor cells, called CSCs,
which are endowed with stem-like features including tumor-
initiating and metastasis formation capabilities. In addition to the
intrinsic characteristics of CSCs, interactions with TME are crucially
involved in the resistance to chemo and targeted therapies.
The mechanisms sustaining CSC/TME crosstalk and the
limitations of targeting this complex signaling network have been
comprehensively described in this review. Specifically, the reasons of
treatment failure using the most recently available compounds
targeting both CSCs or TME components have been reported. Of
note, CSC plasticity and ability to adapt to the metabolic
demand are the major hurdles in targeting CSC/TME interplay.
Therefore, additional studies are needed to develop potential
promising strategies to overcome cancer progression and
drug refractory.Frontiers in Oncology | www.frontiersin.org 13AUTHOR CONTRIBUTIONS
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